二氯二茂钛用于晚期肾细胞癌的II期试验。
Phase II trial of titanocene dichloride in advanced renal-cell carcinoma.
作者信息
Lümmen G, Sperling H, Luboldt H, Otto T, Rübben H
机构信息
Department of Urology, University of Essen, Medical School, Germany.
出版信息
Cancer Chemother Pharmacol. 1998;42(5):415-7. doi: 10.1007/s002800050838.
PMID:9771957
Abstract
Titanocene dichloride was capable of inhibiting the growth of different types of human tumors in vitro. A total of 14 patients with metastatic renal-cell carcinoma (RCC) received 270 mg/m2 titanocene dichloride every 3 weeks for 6 weeks. Although the toxicities and side effects encountered were mild to moderate, no partial or complete response was detectable. In conclusion, titanocene dichloride has no advantage in the therapy of RCC.
摘要
二氯二茂钛能够在体外抑制不同类型人类肿瘤的生长。总共14例转移性肾细胞癌（RCC）患者每3周接受270mg/m²二氯二茂钛治疗，持续6周。尽管所遇到的毒性和副作用为轻度至中度，但未检测到部分或完全缓解。总之，二氯二茂钛在RCC治疗中没有优势。
Zotero 插件